drugset / Trial / NCT03979274
A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers
Phase 1
Completed
44 enrolled
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
RandomizedCrossoverOpen-labelOther
Summary
The study investigated the bioequivalence between the new and the approved formulation for levothyroxine.
Timeline
- Start
- 2019-12-06
- Primary completion
- 2020-01-13
- Completion
- 2020-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levothyroxine | Other / unclassified | 600 ug | Oral |
Indications
No indication recorded.